MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
Gritstone bio, Inc. (NASDAQ: GRTS), former, Gritstone Oncology*
Organization & Developments: Gritstone
Parents
Gritstone bio, Inc. (NASDAQ: GRTS), former, Gritstone Oncology*
Children
*Company has a novel self-amplifying mRNA vaccine platform technology
*Gritstone also has a $1.2 billion collaboration with BlueBird Bio (BLUE) which is testing its T cell therapy platform against ten tumor specific targets identified by Gritstone Oncology.
*Gritstone oncology’s EDGE platform has shown 9X improvement in predicting accurate cancer neoantigens compared to publicly available approaches
2019: Gritstone Oncology: Reiterating Buy, High Upside Potential_seekingalpha.com
2021: Gritstone: Interesting Covid Player, Highly Differentiated Market_ seekingalpha.com
2022: Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst_seekingalpha.com
2023: Gritstone bio: Keep An Eye On This Discounted Cancer Vaccine Developer In 2023_ seekingalpha.com
2023: Gritstone bio: Renewed Excitement For Its COVID-19 Vaccine
2024: Gritstone bio lays off 40% of staff following Covid vaccine trial delay
2024: Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
2024: Gritstone files for bankruptcy in hope of keeping cancer vaccine R&D afloat
Jumps
*Key People: Gritstone
Finance & Acquisitions: Gritstone